Detalles de la búsqueda
1.
An oral care self-management support protocol (OrCaSS) to reduce oral mucositis in hospitalized patients with acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation: a randomized controlled pilot study.
Support Care Cancer
; 24(2): 773-782, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26190359
2.
Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.
J Clin Endocrinol Metab
; 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38661071
3.
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Oncoimmunology
; 13(1): 2290787, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38170160
4.
Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001.
Cancers (Basel)
; 16(1)2023 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38201566
5.
Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy.
Clin Nucl Med
; 47(7): 651-652, 2022 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35085172
6.
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
J Immunother Cancer
; 10(2)2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35217575
7.
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Immunotherapy
; 13(2): 125-141, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33172323
8.
[Management of adverse events in immune oncology - Practical aspects of immune-related adverse events during immune oncological treatment]. / Nebenwirkungsmanagement in der Immunonkologie.
Dtsch Med Wochenschr
; 144(5): 346-353, 2019 03.
Artículo
en Alemán
| MEDLINE | ID: mdl-30699440
9.
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer.
JCO Precis Oncol
; 32019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32914023
Resultados
1 -
9
de 9
1
Próxima >
>>